Revvity RVTY Diagnostics — D&A
Discontinued — last reported Q1 '26
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Revvity in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The official record: Revvity’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Revvity's diagnostics — d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Revvity's diagnostics — D&A?
- Revvity (RVTY) reported diagnostics — D&A of $9.56M in Q1 2026.
- How has Revvity's diagnostics — D&A changed year-over-year?
- Revvity's diagnostics — D&A increased by 39.6% year-over-year, from $6.85M to $9.56M.
- What is the long-term trend for Revvity's diagnostics — D&A?
- Over 2 years (2021 to 2023), Revvity's diagnostics — D&A has grown at a -15.5% compound annual growth rate (CAGR), from $214.18M to $153.1M.
- What does diagnostics — D&A mean?
- This is the non-cash expense allocated to the diagnostics segment to account for the gradual wear and tear of physical assets and the expiration of intangible assets over their useful lives. It reflects the cost of maintaining the segment's capital base.